TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Rectal Infiltration of Exparel for Analgesic Benefit Following Hemorrhoidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing hemorrhoidectomy for grade 3 or 4 hemorrhoids who are English-speaking patients, 21-65 yr of age, ASA physical status I-III, BMI\<30~Exclusion Criteria:~* contraindications to administration of local anesthesia (e.g., local anesthetic allergy), difficult airway (Mallampati\>2), psychiatric or cognitive disorders, pregnancy , and history of substance abuse or chronic opioid use

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Exparel (Type: ACTIVE_COMPARATOR): 266mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
- Bupivacaine HCl with epinephrine (Type: ACTIVE_COMPARATOR): 75mg/30mL 0.25% Bupivacaine HCl with epinephrine
- Normal Saline (Type: PLACEBO_COMPARATOR): 30mL Normal Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Epidermal Cells Delivery and Acute Burns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Thermal burns requiring surgical debridement~* Area involved \< 1260cm²~Exclusion Criteria:~* local or systemic infection~* conditions that would interfere with wound healing (diabetes, hypertension, inflammatory diseases treated by corticoids)~* hypersensitivity to trypsin

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Treatment of acute burn in adults and children by epidermal cell spray
- 2 (Type: ACTIVE_COMPARATOR): Treatment of acute burn in adults and children by classic skin grafts

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ex-situ Normothermic Perfusion Versus Cold Storage in the Transplant With Steatotic Liver Graft.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~LIVER DONOR:~* Donors older than 16 years~* Liver donation grafts due to brain death~* Steatosis confirmed by histological study (between 30% and 60% of macrovesicular steatosis)~LIVER RECIPIENT:~* Adult patients (18 years or older)~* Active liver transplant waiting list candidate~* Able to give informed consent~Exclusion Criteria:~LIVER DONOR:~* Living donors~* Liver destined to the transplant split~* Donor age \<16 years~* Donation after death due to asystole.~* When the biopsy establishes a steatosis ≥ 50%, patients who fulfill at least 3 of the following 5 risk factors will be excluded: Transaminases (AST and ALT) ≥ 200 U / L; Age ≥ 55 years; Hypernatremia ≥ 155 mEq / L; Cardiovascular risk factors, at least 2 of the following 5: DM, HTA, IMC ≥ 35, Active smoking, ischemic stroke; Days of stay in ICU ≥ 4 days with vasoactive drugs (noradrenaline or dobutamine at any dose)~LIVER RECIPIENT:~* Age under 18~* Acute/fulminant hepatic failure~* Transplant of more than one organ (for example, liver and kidney)~* Rejection of informed consent~* Unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Static cold storage (SCS) (Type: EXPERIMENTAL): Traditional method of organ preservation which involves flushing of cold preservation solution following complete dissection and interruption of blood supply to the donor organ. Although cold preservation slows metabolism by 10- to 12-fold, substantial anaerobic activity continues even at ice temperature. This lead to the generation of reactive oxygen species that are the basis of ischaemia-reperfusion injury, when the organ is re-exposed to oxygenated blood at the time of transplantation. This damage, exacerbated by any prior injury, limits the maximum safe preservation time of the donor organ.
- Normothermic machine perfusion (NMP) (Type: EXPERIMENTAL): The main goal of NMP is to optimize graft preservation by mimicking physiological conditions. The perfused organ is supplied with nutrients and oxygen to maintain metabolic hemostasis. Under these conditions, ATP and glycogen reserves can be maintained or actively restored. At the same time, toxic products from the cellular milieu are continuously eliminated, so the cell-mediated injury phase of reperfusion injury can be minimized. Thus, ischemic injury is avoided and the activation of cell death cascades is prevented. This allows both hepatocellular and biliary protection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mobile Tele-rehabilitation Solution for Obese Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Body Mass Index \> 30 kg/m²~* Age 20-65 years~Exclusion criteria:~* Unstabilized primary pathologies (cardiovascular, renal, metabolic, psychiatric)~* No internet access at home

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Telemouv (Type: EXPERIMENTAL): Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
- No intervention (Type: NO_INTERVENTION): Regular follow-up with advice on physical activity and nutrition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Respiratory Training in Lymphoma Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - 80~* Primary cancer diagnosis of lymphoma~* Able and willing to participate in a supervised exercise program at the Anschutz Health and Wellness Center~* Provides a signed physician exercise clearance form~* SBP \&gt; 120 mmHg~* Completion of curative cancer treatment over 12 months prior (individuals on maintenance therapy will be included)~* Possession of a smartphone compatible with the IMST training application (available on both Android and Apple).~Exclusion Criteria:~* oSecond active cancer diagnosis~* oPlanned active cancer treatment or change in current treatment in the next 6 months~  * Severe obesity (BMI \&gt; 40 kg/m2) or underweight (BMI \&lt; 18.5 kg/m2)~ * Unstable weight (\&gt; 3 kg change in body mass in last 3 months)~ * Significant metabolic disorder (e.g. diabetes type II)~ * Uncontrolled thyroid disease~ * Recent changes in hypertensive medication (within last 3 months)~ * Any medical condition that would impact the safety of, or participation in, an exercise program, including:~ * Significant pulmonary conditions such as chronic obstructive pulmonary disease, emphysema, or interstitial lung disease~ * Known cardiovascular disease, significant hypertension (\&gt; 180/120), or a recent cardiac event (within past 6 months)~ * Orthopedic conditions such as advanced osteoarthritis, mobility-limiting amputations or chronic injuries, or mobility-limiting acute orthopedic injuries~ * Advanced rheumatoid arthritis or chronic widespread pain conditions such as fibromyalgia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lymphoma Survivors IMST (Type: EXPERIMENTAL): Participants will undergo a version of the BfitBwell Cancer Exercise Program physical assessment, which assesses physical fitness and function.
- Lymphoma Survivors sham IMST (Type: EXPERIMENTAL): Participants will undergo a version of the BfitBwell Cancer Exercise Program physical assessment, which assesses physical fitness and function.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Innate Immune Response and Enteric Nervous System in Crohn's Disease.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histological preparations (tissue samples) from patients with Crohn's disease who have undergone bowel resection at Aalborg University Hospital in the period from 2012 to 2023.~Exclusion Criteria:~* If the tissue material does not include the ileocecal region.~* If the pathology report does not indicate that there is tissue material from both inflamed and non-inflamed areas.~* If the patient has registered a prohibition against research in the Tissue Utilization Registry.~* The selection of cases starts with the most recent (by date) and stops when 25 suitable cases are found.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Optimal EGM Configuration for Morphology Discrimination

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must already have an implanted St. Jude Medical dual chamber ICD with a dual coil defibrillator lead.~2. Patients must be willing to sign an informed consent form.~3. Patients must have frequent PVCs (minimum of 30/hour)~Exclusion Criteria:~1. Known history of slow VT (under 160 bpm).~2. Patients under the age of 18 years.~3. Pregnant women.~4. Pacemaker dependent rhythm.~5. Ongoing angina pectoris.~6. Current NYHA Class 3-4 heart failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ICD patient with frequent PVCs (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Probaclac in Irritable Bowel Syndrome in Children Aged 8 to 18 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children 8 to 18 years~* Irritable bowel syndrome according to Rome III criteria~Exclusion Criteria:~* Not able to collaborate~* Known Digestive malformation~* History of digestive surgery (except hernia repair and appendectomy)~* History of known digestive disease (Crohn's, ulcerative colitis, esophagitis, peptic ulcer, celiac disease)~* Symptoms suggestive of organic disease (such as rectal bleeding, weight loss~* History of chronic extra-digestive disease~* Acute gastroenteritis in th e4 weeks prior to inclusion~* Central catheter, artificial cardiac valve, endocardiac prothesis~* Current Antidepressant treatment~* Patients taking a treatment for irritable bowel syndrome unable to cease their current treatment~* Patient taking regularly probiotics and natural products

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Probaclac (Type: EXPERIMENTAL): Administration of Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™) b.i.d.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Peri-articular Injection of Bupivacaine With and Without Epinephrine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be male or female of any race~* Ages 18-80yr~* Patients must be undergoing hip or knee arthroplasty~* Patients must be able to understand and be willing to cooperate with study procedures~* Patient must not take platelet inhibiting drugs for 10 days before surgery~* Able to provide written and verbal informed consent~* Preoperative hemoglobin above 12g/dl~* Osteoarthritis as the primary indication for knee arthroplasty, and either osteoarthritis or avascular necrosis as the indication for total hip arthroplasty~Exclusion Criteria:~* Allergy or intolerance to the study materials or medications~* Surgical intervention during the past month for the treatment of the painful joint or its underlying etiology~* History of any substance abuse or dependence within the last 6 months~* Patients who have received an investigational drug or device in the past 30 days~* Affected joint has undergone prior open surgery~* Patient received epoetin alfa 30 days before surgery~* Pre-operative autologous blood donation~* Use of platelet inhibiting drugs 10 days prior to surgery

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Intra-articular Injection of Marcaine/Epinephrine
- 2 (Type: ACTIVE_COMPARATOR): Intra-articular Injection of Marcaine alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Contoura Vision Outcomes Programmed Using the Manifest Refraction Verses Using Phorcides Planning Software in Patients With Oblique Astigmatism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years old and above~* Preoperative total corneal Pachymetry 490um or above~* BCVA 20/20 or better~* Stable refractive error \<0.50D MRSE change in preceding year~* Good general and ocular health~* Preoperative exam completed within three months of surgery~* Soft contact lens wear discontinued 3 days prior to preoperative exam and the procedure~* Residual stromal bed greater than 270um~* Candidates who qualify for Contoura treatment OU (≤ -8.0 D SPH and ≤ -3.0 D CYL)~* Candidates who elect to target both eyes targeted for emmetropia~* ≤ -3.0 D Oblique astigmatism as defined as an axis between 30-60 degrees or between 120-150 degrees~Exclusion Criteria:~* Subjects with usual relative and absolute contraindications for LASIK surgery (subjects with severe dry eye, subjects with recurrent corneal erosion, subjects with uncontrolled Glaucoma, subjects with collagen vascular disorders, keratoconus or signs of keratoconus, Uncontrolled Diabetes, Herpes, corneal dystrophies or degeneration; any irregular astigmatism)~* Pachymetry below 490~* Autoimmune or immunodeficiency diseases, Pregnant or nursing women~* Subjects with signs of inability to understand consent for study and procedure planned~* Subjects with history of previous ocular surgery~The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.~Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Contoura LASIK with Phorcides planning strategy (Type: None): None
- Contoura LASIK with manifest refraction planning strategy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Micro-Patterned Foley Catheter to Reduce Catheter-Associated Urinary Tract Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Veteran~* Hospitalized in one of the two participating Spinal Cord Injury Units~* Require a size 14, 16, or 18 French catheter~* Sign and date the written informed consent document acknowledging his/her desire to participate in the study, or if unable to sign due to spinal cord injury give verbal consent in front of two impartial witnesses who sign and date the informed consent document in the presence of the participant~* Be able to understand and comply with written and verbal protocol requirements, instructions, and protocol-stated restrictions~* Require insertion or exchange of a Foley catheter for no longer than 15 days.~Exclusion Criteria~* Unable to provide informed consent~* Has a current symptomatic urinary tract infection~* Has persistent bacteriuria that cannot be cleared with antimicrobial agents to a nominal level of less than 1,000 Colony Forming Units/mL prior to study catheter insertion~* Has a known bloodstream infection or an infection that requires prolonged antibiotic therapy~* Has periurethral inflammation or infection~* Has a known urethral anatomical anomaly which makes catheterization difficult~* Has a known silicone allergy or sensitivity~* Cannot accommodate a size 14,16 or 18 French Foley catheter.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Micro-Patterned Foley Catheter (Type: EXPERIMENTAL): Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
- Standard-of-Care Foley Catheter (Type: ACTIVE_COMPARATOR): Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Symptomatic moderate or severe chronic GVHD patients in need of a change of systemic immunosuppressant (IS) therapy~* Women of child bearing potential must have a negative pregnancy test and use reliable methods of contraception~Exclusion Criteria:~* Clinically significant medical conditions including active or uncontrolled infections, new or recurrent malignancy, serious cardiac, pulmonary, or renal disease, and uncontrolled diabetes.~* Karnofsky Performance Score \< 60.~* Immunosuppressant therapies other than allowed background therapy~* Anti-arrhythmic and heart rate lowering drugs.~* Any other circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ponesimod (Type: EXPERIMENTAL): Study treatment consists of 3 consecutive periods: 5 mg ponesimod treatment period (including up-titration), 10 mg treatment period (including up-titration) and a 20 mg treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid Versus Placebo to Reduce Perioperative Bleeding After Major Hepatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signature of the consent form~* Patients with hepatic lesion needing a major hepatectomy (≥ 3 hepatic segments)~Exclusion Criteria:~* Absence of signature of the consent form~* Patient with cirrhosis~* Minor hepatectomy (\< 3 hepatic segments)~* Hepatectomy associated with vascular resection~* Contraindication of tranexamic acid : history of arterial or venous thrombosis , disseminated intravascular coagulation, severe renal insufficiency, history of epilepsies , intrathecal or intraventricular injection~* Pregnant or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- acid tranexamic (Type: EXPERIMENTAL): acid tranexamic
- 2 (Type: PLACEBO_COMPARATOR): Nacl 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues